The following criteria for assessing adverse events were used: Often (≥ 1/10), often (≥ 1/100 and <1/10), infrequently (≥ 1/1 000 and <1/100), rarely (≥ 1/10 000 and <1/1 000), rarely (<1/10 000, including individual messages). Frequency categories were formed on the basis of clinical studies of the drug and post-registration surveillance.
The drug Latsipil® is well tolerated. Some patients may experience mild side effects associated with peripheral vasodilation. The most frequent were side effects such as headache, dizziness, "tides" of blood to the skin of the face, a feeling of palpitations. They were transient in nature and, as a rule, disappeared during further therapy with the continued use of the drug Lazipil® at the recommended dose.
From the nervous system
Often: headache, dizziness
Rarely: tremor, depression, mood lability
From the side of the cardiovascular system
Often: heart palpitations, tachycardia, blood tides to face skin
Infrequently: worsening of the course of concomitant angina (identified in a small number of patients usually at the beginning of treatment, more likely in patients with clinically severe coronary heart disease), fainting, marked lowering of blood pressure
From the gastrointestinal tract
Often: discomfort in the stomach, nausea, constipation
Infrequently: hypertrophic gingivitis
Laboratory indicators
Often: reversible increase in alkaline phosphatase activity
From the skin and subcutaneous fat
Often: skin rash (including erythema and itching)
Rarely: angioedema, urticaria
From the side of the kidneys and urinary tract
Often: polyuria
General reactions
Often: asthenia, peripheral edema, weakness